Innovation in bone healing and tissue repair

CYT003 is a product that can be applied in different indications and hence not a platform. The concept of packaging Oligos into Qbeta could be seen as a platform but this would than not be CYT003.

CYT003 is a biological carrier filled with an activating ligand (agonist) of Toll-like receptor 9 (TLR9), a key mediator of innate immunity. TLR9 is the receptor that detects the presence of microbial DNA and induces the immune system’s first line of defense against bacterial infection. The TLR9 agonist of CYT003 is a synthetically produced oligonucleotide containing non-methylated CpG motifs as found in bacterial DNA and belongs to the class of A-type CpGs.

Toll-like receptors are expressed in a subset of immune cells called antigen-presenting cells (APCs; e.g. dendritic cells, macrophages, B-cells). APCs are typically found in tissues in contact with the external environment (skin, lining of the nose, lungs, stomach and intestines) and serve as an important element of the immune defense. APCs, and in particular dendritic cells, communicate with T-cells to orchestrate the immune response when challenged by bacteria or viruses.

TLR9 is predominantly expressed in plasmacytoid dendritic cells (pDCs) and B-cells in humans. CYT003 is actively taken up by pDCs, activates TLR9, and induces the production of type 1 helper T cell (Th1) cytokine IFN-alpha and the co-stimulatory molecule ICOS-Ligand.

CYT003 has been tested in multiple clinical studies and was shown to have a good safety and tolerability profile in more than 700 patients. Checkmate Pharmaceuticals Inc. of Cambridge, MA, USA, acquired an exclusive license to develop CYT003 in the field of oncology. In April 2016, a first melanoma patient was dosed in a Phase 1b clinical trial with CMP-001, formerly known as CYT003. The trial is designed as a multi-center, open-label study of CMP-001 in combination with pembrolizumab for patients with advanced melanoma who have either progressed on anti-PD1 therapy or have failed to respond to at least 12 weeks of therapy.

 

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Immune modulation

CYT003 is a product that can be applied in different indications and hence not a platform. The concept of packaging Oligos into Qbeta could be seen as a platform but this would than not be CYT003.

CYT003 is a biological carrier filled with an activating ligand (agonist) of Toll-like receptor 9 (TLR9), a key mediator of innate immunity. TLR9 is the receptor that detects the presence of microbial DNA and induces the immune system’s first line of defense against bacterial infection. The TLR9 agonist of CYT003 is a synthetically produced oligonucleotide containing non-methylated CpG motifs as found in bacterial DNA and belongs to the class of A-type CpGs.

Toll-like receptors are expressed in a subset of immune cells called antigen-presenting cells (APCs; e.g. dendritic cells, macrophages, B-cells). APCs are typically found in tissues in contact with the external environment (skin, lining of the nose, lungs, stomach and intestines) and serve as an important element of the immune defense. APCs, and in particular dendritic cells, communicate with T-cells to orchestrate the immune response when challenged by bacteria or viruses.

TLR9 is predominantly expressed in plasmacytoid dendritic cells (pDCs) and B-cells in humans. CYT003 is actively taken up by pDCs, activates TLR9, and induces the production of type 1 helper T cell (Th1) cytokine IFN-alpha and the co-stimulatory molecule ICOS-Ligand.

CYT003 has been tested in multiple clinical studies and was shown to have a good safety and tolerability profile in more than 700 patients. Checkmate Pharmaceuticals Inc. of Cambridge, MA, USA, acquired an exclusive license to develop CYT003 in the field of oncology. In April 2016, a first melanoma patient was dosed in a Phase 1b clinical trial with CMP-001, formerly known as CYT003. The trial is designed as a multi-center, open-label study of CMP-001 in combination with pembrolizumab for patients with advanced melanoma who have either progressed on anti-PD1 therapy or have failed to respond to at least 12 weeks of therapy.